A correlation found between psychiatric disorders and events during the prenatal stage

Medical Xpress | February 01, 2019

Particular genetic variants in the human genome that are important for the development of the brain early in the life of the fetus are frequently found in psychiatric disorders. This is shown by a study carried out by iPSYCH. Researchers studied a total of 8 million genetic variants and found that some of them occur particularly often in people who have one or more of the following psychiatric disorders: schizophrenia, depression, bipolar disorder, autism, and ADHD. This background is provided by Professor Thomas Werge from the Mental Health Services & University of Copenhagen and the Lundbeck Foundation's Initiative for Integrated Psychiatric Research, commonly referred to as iPSYCH, which has received a total of DKK 361 million in funding from the Lundbeck Foundation.

Spotlight

In this episode of TalkingSense we’re talking some sense with Craig Rosenberg, Chief Analyst and Co-founder of TOPO. We’ll go behind the scenes of the building of TOPO as well as get the CliffsNotes version of their recent ABM study.

Spotlight

In this episode of TalkingSense we’re talking some sense with Craig Rosenberg, Chief Analyst and Co-founder of TOPO. We’ll go behind the scenes of the building of TOPO as well as get the CliffsNotes version of their recent ABM study.

Related News

MEDICAL

Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines

Be Bio | May 20, 2022

Be Biopharma, Inc. (“Be Bio”) and National Resilience, Inc. (Resilience) today announced a strategic collaboration to advance initial programs in Be Bio’s rare disease pipeline. Be Bio’s proprietary engineered B Cell Medicines (BeCM) platform is harnessing the power of the human B cell to create a new class of autologous and allogeneic cellular medicines that durably and redosably produce therapeutic proteins in vivo without toxic pre-conditioning. The two companies are investing to drive innovation and reliability in cell therapy manufacturing, a critical success factor for broad and meaningful patient impact. As part of this unique partnership, Resilience will dedicate personnel solely to produce and supply Good Manufacturing Practices (GMP)-grade viral vector and cell therapy drug product for the initial programs in Be Bio’s rare disease pipeline. Through a creative cost and risk-sharing model, Resilience will be responsible for manufacturing costs and receive potential future milestones and royalties. Over the past year, Be Bio has built a strong foundation with our BeCM platform, pipeline, team, and recent $130 million financing. Manufacturing is critical to rapidly progress our BeCMs to the clinic and we have built non-GMP manufacturing capabilities in our Cambridge facility. This deal allows us to drive GMP manufacturing with an outstanding partner, and in a capital efficient manner, Resilience’s broad manufacturing capabilities, strong collaborative spirit and dedicated resources to our platform, make them an ideal partner for our BeCM programs.” Joanne Smith-Farrell, Ph.D., Chief Executive Officer at Be Bio. Resilience will lead clinical GMP manufacturing of both the viral vector and the cell therapy drug product for Be Bio’s initial rare disease programs to support first-in-human clinical trials. Resilience will apply its pioneering bioprocessing solutions and network of cell therapy sites, including facilities in Research Triangle Park, NC, Philadelphia, PA, Waltham, MA and Marlborough, MA to conduct the work. This collaboration shows our excitement for the promising science of Be Bio’s proprietary BeCM platforms, and our confidence in their expertise to deliver transformative cell therapies, By working alongside Be Bio early in the drug development process, we aim to accelerate the development of their B cell medicines with the potential to unlock a pipeline of product candidates across a variety of serious diseases.” Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. About B Cells – A New Class of Cellular Medicines Imagine what could “Be?” In nature, a single B cell engrafts in the bone marrow and can produce thousands of proteins per second at constant levels over decades. B cells are nature’s exquisite medicine factories, manufacturing proteins to fight disease and maintain health. Unleashing the power of B cells is driving a new class of cellular medicines – Engineered B Cell Medicines (BeCM). BeCMs have the potential to be durable, allogeneic, redosable and administered without toxic conditioning. The promise of BeCMs could transform therapeutic biologics with broad application — across protein classes, patient populations and therapeutic areas. About Be Biopharma Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute. Be Bio is backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb and Takeda Ventures. Since our founding, Be Bio’s investors have committed over $180 million to enable the Company to re-imagine medicine based on the power of B cell therapy. About Resilience Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives by continuously advancing the science of biopharmaceutical manufacturing and development.

Read More

MEDICAL

Agilent Announces Collaboration with APC on Real-Time Process Monitoring

Agilent Technologies | May 31, 2022

Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography (LC). Agilent has selected to partner with APC, a provider of innovative small molecule and large molecule process design and process development solutions. Both APC and Agilent pursue similar goals, which are focused on helping customers in the biopharmaceutical and pharmaceutical industry to improve the human condition and to delivering life-changing drugs to market faster and more efficiently. The collaboration between the companies leverages their complementary strengths to develop specific workflows, which bridge the gap between the analytical and process solutions. We are delighted to be collaborating with APC on a solution for real-time/automated process monitoring, Adapting our analytical capabilities to support online process monitoring requirements reflects the current trend within the pharma and biopharma industry towards continuous manufacturing and helps our mutual customers to develop higher quality drugs faster.” Stefan Schuette, vice president and general manager of Agilent’s Liquid Phase Separations Division. Agilent is a leader in the analytical lab with a comprehensive portfolio of analytical equipment for the biopharma and pharma industry, This collaboration leverages our complementary strengths and ultimately provides even better services and technologies to our customers by giving them greater insights into, and control of, their processes.” Damian Connolly, Analytical Lead at APC. The results obtained during the collaboration will be shared with customers via applications notes and joint webinars, which will also showcase the recently launched InfinityLab Online LC and InfinityLab Bio LC portfolio from Agilent. These new product offerings and the collaboration with APC ensure a leading position in the trend towards continuous manufacturing, process analytical technology (PAT), and real-time release testing (RTRT) in the biopharmaceutical and pharmaceutical industry. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide.

Read More

MEDICAL

Hillstream BioPharma to Announce Collaborating with Sapien Biosciences

Hillstream | June 30, 2022

Hillstream BioPharma, Inc., a U.S.-based biotechnology company developing novel therapeutic candidates targeting ferroptosis for cancer treatment, announced a collaboration with an Indian pioneer biobank and peonalized medicine company that leverages Saarum Innovation's global life sciences research expertise, Sapien Biosciences. The collaboration is aimed at assessing the compatibility of HSB-1216 with immune checkpoint inhibitors. HSB-1216, Hillstream’s most advanced candidate, is an IMCD modulator that targets various types of solid tumors. In an exhaustive study in Germany, the active drug in HSB-1216 was found to be efficacious in a clinical pilot for devastating cancers, including epithelial carcinomas and triple-negative breast cancer. Hillstream aims to build an early clinical proof-of-concept by beginning a clinical investigation with HSB-1216 in 2022. With this collaboration, Hillstream will be able to use Sapien’s patient samples and rich datasets to validate its HSB-1216 for the development of novel cancer therapeutics. We are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody.” He stated, “In addition, we will also study the potential synergistic effects of HSB-1216 with the recently approved Bristol Myers Squibb drug Opdualag® (nivolumab + relatlimab), a fixed dose combination of an anti-PD1 MAb + anti-LAG3 MAb, to demonstrate that targeting a ferroptosis-associated metabolism in tumors may improve the efficacy of cancer immunotherapy.” Randy Milby, Hillstream’s Chief Executive Officer. We are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology and Immune-oncology Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple negative breast cancer cells which were presented at AACR 2020.” Dr. Jugnu Jain, CEO, Sapien Biosciences.

Read More